Lotte Biologics

Executive Summary

Lotte Biologics is a Boston-based contract development and manufacturing organization (CDMO) that provides biologics manufacturing services to pharmaceutical companies. Founded in 2022, the company is privately held and operates at a commercial stage, employing between 200 and 500 people. As a relatively new entrant in the competitive CDMO landscape, Lotte Biologics leverages its expertise in biologics to offer end-to-end solutions from development to commercial manufacturing. The company's strategic location in Boston, a hub for biopharma innovation, positions it well to capture demand from emerging biotechs and established pharma alike. Given its recent founding and the capital-intensive nature of biologics manufacturing, Lotte Biologics is likely focused on scaling its operations and building a robust client pipeline. The company's private status and lack of disclosed funding or valuation suggest it may be in a growth phase, potentially seeking to expand capacity or form strategic partnerships. While the CDMO market is crowded, Lotte's specialized focus and parent company support (Lotte Group) could provide competitive advantages. Near-term catalysts include the ramp-up of new manufacturing lines, securing long-term contracts with key clients, and potentially announcing a significant capacity expansion project.

Upcoming Catalysts (preview)

• Q4 2026Announcement of major capacity expansion60% success
• Q1 2027Securing a multi-year contract with a top-20 pharma company40% success
• Q2 2027FDA approval of a client's biologic drug manufactured by Lotte Biologics30% success